Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

NCT04196205 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia ,Lymphomas

Interventions

BIOLOGICAL: Anti-CD19 CAR-T

Sponsor

The First Affiliated Hospital of Nanchang University